Onkologie - spezialisierte Tumortherapie

Peritonealkarzinose - Bauchfellkarzinose - Bauchfellkrebs
chirurgische Onkologie - regionale Chemotherapie - Peritonektomie


  1. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Sarnaik AA, Sussman JJ, Ahmad SA, Lowy AM. Surg Oncol Clin N Am. 2003 Jul;12(3):849-63
  2. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Ann Surg Oncol. 2003 Mar;10(2):155-62
  3. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. Anticancer Res. 2003 May-Jun;23(3C):3019-27.
  4. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, McQuellon R, Geisinger KR, Loggie BW. Arch Surg. 2003 Jan;138(1):26-33.
  5. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. van Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA. Anticancer Res. 2003 Mar-Apr;23(2B):1501-8.
  6. Heated chemotherapy improves survival and quality of life in peritoneal carcinomatosis patients. Rollins G. Rep Med Guidel Outcomes Res. 2003 Feb 7;14(3):8-9. No Abstract Available.
  7. Computed tomographic features of peritoneal carcinomatosis treated by intraperitoneal chemohyperthermia. Dromain C, Bisdorff A, Elias D, Antoun S, Boige V, Lasser P, Sigal R. J Comput Assist Tomogr. 2003 May-Jun;27(3):327-32.
  8. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN. J Clin Oncol 2003 Mar 1,21(5):762-4
  9. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Ann Surg Oncol 2003; 10(3):210-212
  10. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. Deraco M, Gronchi A, Mazzaferro V, Vaglini M et al. Tumori 2002 Sep-Oct; 88(5):370-5
  11. Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion. Sutton SW, Yancey LW, Chase VA et al. Perfusion 2002 Nov;17(6):441-6
  12. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Panteix G, Beaujard A, Garbit F. et al. Anticancer Res 2002 Mar-Apr; 22(2B): 1329-36
  13. Cytoreduction and hyperthermic-antiblastic peritoneal (HAPP) in peritoneal carcinomatosis [in italian] Vaira M, Scoderi S, Costamagna D et al. Minerva Chir 2002 Oct: 57(5): 597-605
  14. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Begossi G, Gonzalez-Moreno S, Ortega-Perez G, et al. Eur J Surg Oncol 2002; 28(1),80-87
  15. Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Kunisaki C, Shimada H, Nomura M et al. Surgery 2002 May: 131(5): 521-8
  16. Chemohyperthermia for advanced abdominal malignancies: a new procedure with closed abdomen and previously performed anastomosis. Zanon C, Clara R, Bortolini M, Malossi A, Moscato R, Celoria P, de Andrea M, Rizzo M, Chiappino I, Grazia Sciuto M, Mussa A. Int J Hyperthermia. 2001 Sep-Oct;17(5):456-64.
  17. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Hager ED, Dziambor H, Hohmann D, Muhe N, Strama H. Int J Gynecol Cancer. 2001;11 Suppl 1:57-63.
  18. Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis. Sugarbaker PH, Yonemura Y. Hepatogastroenterology 2001; Sept-Oct; 48(41): 1238-47
  19. Rational and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Witkamp AJ, de Bree E, Van Goethem R et al. Cancer Treat Rev 2001 Dec: 27(6): 365-74
  20. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Sugarbaker PH. Jpn J Clin Oncol 2001 Dec: 31(12): 573-83
  21. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. M. Deraco, CR Rossi, et al and Maurizio Vaglini. Tumori 2001; 87(3):120-126
  22. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. D. Elias, F. Blot, A. El Otmany et al. Cancer 2001; 92:71-76
  23. Patients with pseudomixoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favourable prognosis than patients with peritoneal mucinous carcinomatosis. BM Ronnet, Hui Yan, RJ Kurman et al. Cancer 2001; 92:85-91
  24. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. AJ Witkamp, E de Bree, MM Kaag et al. Eur J Canc 2001; 37(7), 979-984
  25. ,8°C whole body hyperthermia (WBH) combined with carboplatin in patients with advanced ovarian carcinoma. Dirk Jaeger, Akin Atmaca, Antje Neumann, Jan Unckell, Jacqueline Orth, Elke Jaeger, Alexander Knuth. Annals of Oncology, Vol 11, Suppl.4 October 2000, page 82
  26. Whole body hyperthermia (WBH) at 41,8°C combined with ifosfamide (IFO) and carboplatin (CBDCA) in relapsed ovarian carcinoma pretreated with a platin-containing regimen. Yael Gruber, Susanna Hegewisch-Becker, Afsaneh Bakhshandeh-Bath, Harald Sommer, Rüdiger Hoffmann, Dieter K. Hossfeld. Annals of Oncology, Vol 11, Suppl.4 October 2000, page 85
  27. Treatment of primary colon cancer with peritoneal carcinomatosis. Comparison of concomitant vs. delayed management. Sophie R. Pestieau, Paul H. Sugarbaker. Dis colon rectum, 2000; 10(43), 1341-1348
  28. Results of treatment of 33 patients with peritoneal mesothelioma. G Sebbag, H Yan, BM Shmookler, D Chang, PH Sugarbaker. Br J Surg 2000; 87, 1587-1593
  29. Hyperthermic intraperitoneal chemoperfusion in the treatment of locallt advanced intra-abdominal cancer. WP Ceele, U Hesse, B de Hemptinne and P Pattyn. Br J Surg 2000; 87, 1006-1015
  30. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Zoetmulder FA, Kaag MM, Beijnemn JH. Eur J Surg Oncol 2000; 26(7):663-8
  31. Peritoneal carcinomatosis from non gynecologic malignancies. Results of the EVOCAPE 1 multicentric prospective study. B Sadeghi, C Arvieux, O Glehen et al. Cancer 2000, 88:358-63
  32. Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? Shido A, Ohmura S, Yamamoto k, et al: World J Surg 2000;24, 507-511.
  33. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate refression analysis. Hirose K, Katayama K, Iida A et al. Oncology 1999; 57(2):106-14
  34. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: Phase I-II study. F Gilly, A Beaujard, O. Glehen et al. Anticancer Res; 1999, 19:2317-2322
  35. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. D Tsiftisis, E de Bree, J Romanos et al. Arch Surg 1999; 134:545-549
  36. Second-look surgery after cytoreduction an intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analisys of prognostic features. AG Portilla, PH Sugarbaker, D Chang. World J Surg 1999; 23:23-29
  37. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adducts formation in patients and ovarian cancer lines. PJM van der Vaart, N van der Vange, FAN Zoetmulder et al.; Eur J Cancer 1998; Vol 34, 1, pp 148-154
  38. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. DL Bartlett, JF Buell, SK Libutti, E Reed, KB Lee, WD Figg, DJ Venzon, HR Alexander. Cancer 1998; 83(6), 1251-1261
  39. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Y Yonemura, T Fujiumura, G Nishimura et al. Surgery 1996; 119:437-44
  40. Chemio-ipertermia perfusionale intra-peritoneale (CIPIP). Una nuova tecnica per il trattamento integrato delle neoplasie gastro-intestinali con interessamento peritoneale. M. Pace, A. Galli, D. Brugnola, A. Bellacci. J Chemother vol 8, suppl 3, 1996, pg 83
  41. Isolated perfusion in oncological therapy. A. Galli, A. Bellacci, E. Macera Mascitelli, M. Pace. RBM 4/15, 223, 1993
  42. Bonnefoi H,A'Hern RP,Fisher C,Macfarlane V,Barton D,Blake P,Shepherd JH,Gore ME:Natural history of stage IV epithelial ovarian cancer.J Clin Oncol 1999,17:767-775. Yancik R:Ovarian cancer.Age contrasts in incidence,histology,disease stage at diagnosis,and mortality.Cancer 1993, 71:517-523.
  43. Stephens AD,Alderman R,Chang D,Edwards GD,Esquivel J,Sebbag G,Steves MA,Sugarbaker PH:Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative chemotherapy using the Coliseum technique.Ann Surg Oncol 2000,6:790-796.
  44. Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993, 71:517-523
  45. Abu-Rustum NR, Chi DS, Curtin JP: Epithelial ovarian cancer. Curr Probl Surg 1999, 36:7-53.
  46. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.J Clin Oncol 2002, 5:1248-1259
  47. Kecmanovic DM, Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB: Cytoreductive surgery for ovarian cancer.Eur J Surg Oncol 2003, 29:315-320
  48. Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001, 87:120-126.
  49. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2003, 13:764-770.
  50. Los G, Smals OA, van Vugt MJ, van der Vlist M, den Engelse L, McVie JG, Pinedo HM: A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992, 52:1252-1258.
  51. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003, 21:3737-3743.
  52. Sugarbaker PH, Chang D: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 2000, 6:727-731.
  53. Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, Manns M, Klempnauer J: Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001, 27:286-290
  54. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA: Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003, 10:155-162.
  55. Sugarbaker PH: Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. In: Peritoneal carcinomatosis: drugs and diseases (Edited by: Sugarbaker P). Boston, Kluwer Academic Publishers 1996, 75-86.
  56. Sugarbaker PH: Peritonectomy procedures. Ann Surg 1995, 221:29-42.
  57. Sugarbaker PH: Management of peritoneal-surface malignancy: the surgeons role. Langenbecks Arch Surg 1999, 384:576-587.
  58. Van der Burg MF: Advanced ovarian cancer. Curr Treat Options Oncol 2001, 2:109-118.
  59. Zang RY, Zhang ZY, Cai SM, Li ZT, Chen J, Tang MQ, Liu Q: Effect of cytoreductive surgery on survival of patient with recurrent epithelial ovarian cancer.J Surg Oncol 2000, 75:24-30.
  60. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, Graeff H: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.Cancer 1992, 70:2129-2136.
  61. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophospahmide for stage III ovarian cancer. N Engl J Med 1996, 335:1950-1955
  62. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001, 83:504-512
  63. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001, 92:71-76.
  64. Salom E, Almeida Z, Mirhashemi R: Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 2002, 14:519-527
  65. Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K: Peritoneal cancer index:a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003, 29:69


Literatur zur Hyperthermie

  1. Seegenschmiedt MH, Vernon CC. A historical perspective on hyperthermia in oncology. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 3-44.
  2. Reinhold HS, Endrich B. Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986; 2: 111-137.
  3. Song VE, Choi IB, Nah BS et al. Microvasculature and perfusion in normal tissues and tumours. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 139-156.
  4. Vaupel PW, Kelleher DK. Metabolic status and reaction to heat of normal and tumor tissue. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 157-176.
  5. Raaphorst GP. Fundamental aspects of hyperthermic biology. In Field SB, Hand JW (eds): An Introduction to the Practical Aspects of Clinical Hyperthermia.London: Taylor and Francis 1990; 10-54.
  6. Fajardo LF. Pathological effects of hyperthermia in normal tissues. Cancer Res 1984; 44: 4826s-4835s.[Abstract]
  7. Sminia P, Van der Zee J, Wondergem J, Haveman J. Effect of hyperthermia on the central nervous system: a review. Int J Hyperthermia 1994; 10:1-130.[Medline]
  8. Wondergem J, Haveman J, Rusman V et al. Effects of local hyperthermia on the motor function of the rat sciatic nerve. Int J Radiat Biol 1988; 53: 429-439.
  9. Streffer C. Molecular and cellular mechanisms of hyperthermia. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy andThermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 47-74.
  10. Song CWM, Shakil A, Griffin RJ, Okajima K. Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination withcarbogen. Semin Oncol 1997; 24: 626-632.[Medline]
  11. Kampinga HH, Dikomey E. Hyperthermic radiosensitization: mode of action and clinical relevance. Int J Radiat Biol 2001; 77: 399-408.[Medline]
  12. Stewart FA, Denekamp J. The therapeutic advantage of combined heat and X-rays on a mouse fibrosarcoma. Br J Radiol 1978; 51: 307-316.[Abstract]
  13. Marino C, Cividalli A. Combined radiation and hyperthermia: effects of the number of heat fractions and their interval on normal and tumour tissues. Int JHyperthermia 1992; 8: 771-781.[Medline]
  14. Horsman MR, Overgaard J. Simultaneous and sequential treatment with radiation and hyperthermia: a comparative assessment. In Handl-Zeller L (ed.):Interstitial Hyperthermia. Vienna: Springer Verlag 1992; 11-33.
  15. Dahl O. Interaction of heat and drugs in vitro and in vivo. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy andThermochemotherapy Volume 1. Berlin: Springer Verlag 1995; 103-121.
  16. Skibba JL, Jones FE, Condon RE. Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. Cancer Treat Rep 1982;66: 1357-1363.[Medline]
  17. Ostrow S, Van Echo D, Egorin M et al. Cyclophosphamide pharmacokinetics in patients receiving whole-body hyperthermia. Natl Cancer Inst Monogr 1982;61: 401-403.
  18. Honess DJ, Donaldson J, Workman P, Bleehen NM. The effect of systemic hyperthermia on melphalan pharmocokinetics in mice. Br J Cancer 1985; 51:77-84.[Medline]
  19. Bates DA, Mackillop WJ. The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br J Cancer1990; 62: 183-188.[Medline]
  20. Myerson RJ, Moros E, Roti Roti JL. Hyperthermia. In Perez CA, Brady LW (eds): Principles and Practice of Radiation Oncology, 3rd edition. Philadelphia:Lippincott-Raben Publishers 1997; 637-683.
  21. Coit DG. Hyperthermic isolation limb perfusion for malignant melanoma: a review. Cancer Invest 1992; 10: 277-284.[Medline]
  22. Ceelen WP, Hesse U, De Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. BrJ Surg 2000; 87: 1006-1015.[Medline]
  23. Robins HI, on behalf of SHOWG members. Meeting report. Systemic Hyperthermia Oncological Working Group. Oncology 1995; 52: 260-263.[Medline]
  24. Robins HI, Dennis WH, Neville AJ et al. A nontoxic system for 41.8°C whole-body hyperthermia: results of a phase I study using a radiant heat device. CancerRes 1985; 45: 3937-3944.[Abstract]
  25. Bull JCM. Clinical practice of whole-body hyperthermia: new directions. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy andThermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 303-322.
  26. Cavaliere R, Ciocatto EC, Giovanella BC et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20:1351-1381.[Medline]
  27. Pettigrew RT, Galt JM, Ludgate CM, Smith AN. Clinical effects of whole-body hyperthermia in advanced malignancy. Br Med J 1974; 4: 679-682.[Medline]
  28. Kim JH, Hahn EW, Tokita N, Nisce LZ. Local tumor hyperthermia in combination with radiation therapy. 1. Malignant cutaneous lesions. Cancer 1977; 40:161-169.[Medline]
  29. González González D, Van Dijk JDP, Blank LECM, Rümke PH. Combined treatment with radiation and hyperthermia in metastatic malignant melanoma.Radiother Oncol 1986; 6: 105-113.[Medline]
  30. Hetzel FW, Mattiello J. Interactions of hyperthermia with other modalities. In Paliwal BR, Hetzel FW, Dewhirst MW (eds): Medical Physics Monograph no. 16.Biological, Physical and Clinical Aspects of Hyperthermia. College Park, MD: American Institute of Physics 1987; 30-56.
  31. Manning MR, Cetas TC, Miller RC et al. Clinical hyperthermia: results of a phase I trial employing hyperthermia alone or in combination with external beam orinterstitial radiotherapy. Cancer 1982; 49: 205-216.[Medline]
  32. Dunlop PRC, Hand JW, Dickinson RJ, Field SB. An assessment of local hyperthermia in clinical practice. Int J Hyperthermia 1986; 2: 39-50.[Medline]
  33. Gabriele P, Orecchia R, Ragona R et al. Hyperthermia alone in the treatment of recurrences of malignant tumors. Cancer 1990; 66: 2191-2195.[Medline]
  34. Van der Zee J, Treurniet-Donker AD, The SK et al. Low dose reirradiation in combination with hyperthermia: a palliative treatment for patients with breastcancer recurring in previously irradiated areas. Int J Radiat Oncol Biol Phys 1988; 15: 1407-1413.[Medline]
  35. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989; 16: 535-549.[Medline]
  36. Van der Zee J, Vernon CC. Thermoradiotherapy for advanced and recurrent breast tumours. In Seegenschmiedt MH, Fessenden P, Vernon CC (eds):Thermoradiotherapy and Thermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 35-48.3
  37. Van der Zee J, Van der Holt B, Rietveld PJM et al. Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation.Br J Cancer 1999; 79: 483-490.[Medline]
  38. Rietbroek RC, Schilthuis MS, Bakker PJM et al. Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrentcarcinoma of the uterine cervix. Cancer 1997; 79: 935-943.[Medline]
  39. De Wit R, Van der Zee J, Van der Burg MEL et al. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients withpreviously irradiated recurrent carcinoma of the uterine cervix. Br J Cancer 1999; 80: 1387-1391.[Medline]
  40. Issels RD, Abdel-Rahman S, Wendtner C-M et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary orrecurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 2001; 37: 1599-1608.[Medline]
  41. Wendtner C-M, Abdel-Rahman S, Baumert J et al. Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults:results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001; 37: 1609-1616.[Medline]
  42. Westermann AM, Grosen EA, Katschinski DM et al. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur JCancer 2001; 37: 1111-1117.[Medline]
  43. Wiedemann GJ, Robins HI, Gutsche S et al. Ifosfamide, carboplatin and etoposid (ICE) combined with 41.8°C whole body hyperthermia in patients withrefractory sarcoma. Eur J Cancer 1996; 32A: 888-892.
  44. Van Heek R, D'Oleire F, Havers W. Thermoradiotherapy and thermochemotherapy for pediatric tumors. In Seegenschmiedt MH, Fessenden P, Vernon CC(eds): Thermoradiotherapy and Thermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 187-205.
  45. Wessalowski R, Ruck H, Pape H et al. Hyperthermia for the treatment of patients with malignant germ cell tumors. A phase I/II study in ten children andadolescents with recurrent or refractory tumors. Cancer 1998; 82: 793-800.[Medline]
  46. Perez CA, Gillespie B, Pajak T et al. Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a report by the RadiationTherapy Oncology Group. Int J Radiat Oncol Biol Phys 1989; 16: 551-558.[Medline]
  47. Perez CA, Pajak T, Emami B et al. Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors.Final report by the Radiation Therapy Oncology Group. Am J Clin Oncol 1991; 14: 133-141.[Medline]
  48. Emami B, Scott C, Perez CA et al. Phase III study of interstitial thermoradiotherapy compared with interstitial radiotherapy alone in the treatment of recurrent orpersistent human tumors: a prospectively controlled randomized study by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1996; 34:1097-1104.[Medline]
  49. Valdagni R, Amichetti M, Pani G. Radical radiation alone versus radical radiation plus microwave hyperthermia for N3 (TNM-UICC) neck nodes: aprospective randomized clinical trial. Int J Radiat Oncol Biol Phys 1988; 15: 13-24.[Medline]
  50. Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastaticlymphnodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1993; 28: 163-169.
  51. Overgaard J, González González D, Hulshof MCCM et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignantmelanoma. Lancet 1995; 345: 540-543.[Medline]
  52. Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from fiverandomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996; 35: 731-744.[Medline]
  53. Sneed PK, Stauffer PR, McDermott W et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia forglioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 287-295.[Medline]
  54. Van der Zee J, González González D, Van Rhoon GC et al. for the Dutch Deep Hyperthermia Group. Comparison of radiotherapy alone with radiotherapy plushyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet 2000; 355: 1119-1125.[Medline]
  55. Berdow BA, Menteshashvili GZ. Thermoradiotherapy of patient with locally advanced carcinoma of the rectum. Int J Hyperthermia 1990; 6:881-890.[Medline]
  56. Colombo R, Da Pozzo LF, Gev A et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alonefor superficial bladder cancer. J Urol 1996; 155: 1227-1232.[Medline]
  57. Datta NR, Bose AK, Kapoor HK. Thermoradiotherapy in the management of carcinoma cervix (stage IIIb): a controlled clinical study. Indian Med Gazette1987; 121: 68-71.
  58. Egawa S, Tsukiyama I, Watanabe S et al. A randomized clinical trial of hyperthermia and radiation versus radiation alone for superficially located cancers. J JpnSoc Ther Radiol Oncol 1989; 1: 135-140.
  59. Engelhardt R, Neumann H, Müller U, Löhr GW. Clinical studies in whole body hyperthermia. In Sugahara T, Saito M (eds): Hyperthermic Oncology Volume 2.London: Taylor and Francis 1989; 509-510.
  60. Harima Y, Nagata K, Harima K et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIb cervical carcinoma. Int JHyperthermia 2001; 17: 97-105.[Medline]
  61. Kakehi M, Ueda K, Mukojima T et al. Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer ofdeep-seated organs. Int J Hyperthermia 1990; 6: 719-740.[Medline]
  62. Kitamura K, Kuwano H, Watanabe M et al. Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal carcinoma. JSurg Oncol 1995; 60: 55-58.[Medline]
  63. Kohno I, Kaneshige E, Fujiwara K, Sekiba K. Thermochemotherapy (TC) for gynecologic malignancies. In Overgaard J (ed.): Hyperthermic Oncology Volume1. London: Taylor and Francis 1984; 753-756.
  64. Strotsky AV, Fradkin SZ, Zhavrid EA, Karpovich UA. Combined therapy of bladder cancer with the use of hyperthermia. Strahlenther Onkol 1991; 167:346.
  65. Sugimachi K, Kitamura K, Baba K et al. Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus: aprospective randomized trial. Int J Hyperthermia 1992; 8: 289-295.[Medline]
  66. Wang J, Li D, Chen N. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer. Chung Hua Chung LiuTsa Chih 1996; 18: 51-54.[Medline]
  67. You Q-S, Wang R-Z, Suen G-Q et al. Combination preoperative radiation and endocavitary hyperthermia for rectal cancer: long-term results of 44 patients. IntJ Hyperthermia 1993; 9: 19-24.[Medline]
  68. Datta NR, Bose AK, Kapoor HK, Gupta S. Head and neck cancers: results of thermoradiotherapy versus radiotherapy. Int J Hyperthermia 1990; 6:479-486.[Medline]
  69. Marmor JB, Hahn GM. Combined radiation and hyperthermia in superficial human tumors. Cancer 1980; 46: 1986-1991.[Medline]
  70. Sharma S, Patel FD, Sandhu APS et al. A prospective randomized study of local hyperthermia as a supplement and radiosensitizer in the treatment of carcinomaof the cervix with radiotherapy. Endocuriether Hyperthermia Oncol 1989; 5: 151-159.
  71. Shchepotin IB, Evans SRT, Chorny V et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Surg Oncol1994; 3: 37-44.[Medline]
  72. Sugimachi K, Kuwano H, Ide H et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospectiverandomized trial. Int J Hyperthermia 1994; 4: 485-493.
  73. Lee HK, Antell AG, Perez CA et al. Superficial hyperthermia and irradiation for recurrent breast carcinoma of the chest wall: prognostic factors in 196 tumors.Int J Radiat Oncol Biol Phys 1998; 40: 365-375.[Medline]
  74. Hiraoka M, Jo S, Akuta K et al. Radiofrequency capacitive hyperthermia for deep-seated tumors II. Effect of thermoradiotherapy. Cancer 1987; 60:128-135.[Medline]
  75. Lee CK, Song CW, Rhee JG et al. Clinical experience using 8 MHz radiofrequency capacitive hyperthermia in combination with radiotherapy: results of a phaseI/II study. Int J Radiat Oncol Biol Phys 1995; 32: 733-745.[Medline]
  76. Wust P, Stahl H, Löffel J et al. Clinical, physiological and anatomical determinants for radiofrequency hyperthermia. Int J Hyperthermia 1995; 11:151-167.[Medline]
  77. Cavaliere R, Di Filippo F, Cavaliere F et al. Clinical practice of hyperthermic extremity perfusion in combination with radiotherapy and chemotherapy. InSeegenschmiedt MH, Fessenden P, Vernon CC (eds): Thermoradiotherapy and Thermochemotherapy Volume 2. Berlin: Springer Verlag 1996; 323-345.
  78. Van der Zee J, González González D. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 2002; 18: 1-12.[Medline]
  79. Wust P, Fahling H, Helzel T et al. Design and test of a new multi-amplifier system with phase and amplitude control. Int J Hyperthermia 1998; 14: 459-477.
  80. Van Rhoon GC, Rietveld PCM, Van der Zee J. A 433 MHz Lucite Cone waveguide applicator for superficial hyperthermia. Int J Hyperthermia 1998; 14:13-27.[Medline]
  81. Rietveld PJM, Van Putten WLJ, Van der Zee J, Van Rhoon GC. Comparison of the clinical effectiveness of the 433 MHz Lucite Cone applicator with that of aconventional waveguide applicator in applications of superficial hyperthermia. Int J Radiat Oncol Biol Phys 1999; 43: 681-687.[Medline]
  82. Jordan A, Scholz R, Maier-Hauff K et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluidhyperthermia. J Magnetism Magn Mat 2001; 225: 118-126.
  83. Wust P, Seebass M, Nadobny J et al. Simulation studies promote technological development of radiofrequency phased array hyperthermia. Int J Hyperthermia1996; 12: 477-494.[Medline]
  84. Lagendijk JJW. Hyperthermia treatment planning. Phys Med Biol 2000; 45: R61-R76.[Medline]
  85. Gellermann J, Wust P, Stalling D et al. Clinical evaluation and verification of the hyperthermia treatment planning system Hyperplan. Int J Radiat Oncol BiolPhys 2000; 47: 1145-1156.[Medline]
  86. Carter DL, MacFall JR, Clegg ST et al. Magnetic resonance thermometry during hyperthermia for human high-grade sarcoma. Int J Radiat Oncol Biol Phys1998; 40: 815-822.[Medline]
  87. Hentschel M, Dreher W, Wust P et al. Fast spectroscopic imaging for non-invasive thermometry using the Pr[MOE-DO3A] complex. Phys Med Biol 1999; 44:2397-2408.[Medline]
  88. Yatvin MB, Mühlensiepen H, Porschen W et al. Selective delivery of liposome-associated cis-Dichlorodiammineplatinum(II) by heat and its influence on tumordrug uptake and growth. Cancer Res 1981; 41: 1602-1607.[Abstract]
  89. Matteucci ML, Anyarambhatla G, Rosner G et al. Hyperthermia increases accumulation of Technetium-99M-labeled liposomes in feline sarcomas. Clin CancerRes 2000; 6: 3748-3755.[Abstract/Free Full Text]
  90. Kong G, Anyarambhatla G, Petros WP et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.Cancer Res 2000; 60: 6950-6957.9[Abstract/Free Full Text]
  91. Multhoff G, Botzler C, Wiesnet M et al. A stress-indcible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not onnormal cells. Int J Cancer 1995; 61: 272-279.[Medline]
  92. Multhoff G, Botzler C, Wiesnet M et al. CD-3 large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heatshock protein on human sarcoma cells. Blood 1995; 86: 1374-1384.[Abstract/Free Full Text]
  93. Basu S, Binder RJ, Suto R et al. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells andactivate the NF-B pathway. Int Immunol 2000; 12: 1539-1546.[Abstract/Free Full Text]
  94. Ito A, Shinkai M, Honda H et al. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer ImmunolImmunother 2001; 50: 515-522.[Medline]
  95. Gerner EW, Hersh EM, Pennington M et al. Heat-inducible vectors for use in gene therapy. Int J Hyperthermia 2000; 16: 171-181.[Medline]
  96. Huang Q, Hu JK, Lohr F et al. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res 2000; 60:3435-3439.[Abstract/Free Full Text]
  97. Okamota K, Shinoura N, Egawa N et al. Adnovirus-mediated transfer of p53 augments hyperthermia-induced apoptosis in U251 glioma cells. Int J RadiatOncol Biol Phys 2001; 50: 525-531.[Medline]
  98. Lohr F, Hu K, Huang Q et al. Enhancement of radiotherapy by hyperthermia-regulated gene therapy. Int J Radiat Oncol Biol Phys 2000; 48:1513-1518.[Medline]
  99. Benowitz S. Bone marrow experts are still debating the value of purging. J Natl Cancer Inst 2000; 92: 190-192.[Free Full Text]
  100. Moriyama Y, Narita M, Sato K et al. Application of hyperthermia to the treatment of human acute leukemia: purging human leukemic progenitor cells by heat.Blood 1986; 67: 802-804.[Abstract]
  101. Iwasawa T, Hirabayashi Y, Kubota N et al. Hyperthermic purging in vitro of murine leukemia cells (MK-8057): surviving fractions of normal and leukemicstem cells and the long-term survival of mice injected with the post-hyperthermic leukemia cells. Exp Hematol 1991; 19: 332-337.[Medline]
  102. Osman Y, Moriyama Y, Shibata A. Enhanced elimination of Ph+ chormosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-, TNF,and quercetin): its application to autologous bone marrow transplantation for CML. Exp Hematol 1995; 23: 444-452.[Medline]
  103. Wierenga PK, Setroikromo R, Vellenga E, Kampinga HH. Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of thetherapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH[3]. Br J Haematol 2000; 111: 1145-1152.[Medline]
  104. Griffin RJ, Ogawa A, Song CW. A novel drug to reduce tumor perfusion: antitumor effect alone and with hyperthermia. Radiat Res 2000; 154:202-207.[Medline]
  105. Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol2001; 40: 497-503.[Medline]
  106. Eikesdal HP, Bjerkvig R, Dahl O. Vinblastine and hyperthermia target the neovasculature in BT4AN rat gliomas: therapeutic implications of the vascularphenotype. Int J Radiat Oncol Biol Phys 2001; 51: 535-544.[Medline]
  107. Eikesdal HP, Bjerkvig R, Mella O, Dahl O. Combrestatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiother Oncol2001; 60: 147-154.[Medline]
  108. Kai H, Matsufuji H, Okudaira Y, Sugimachi K. Heat, drugs and radiation given in combination is palliative for unresectable esophageal cancer. Int J RadiatOncol Biol Phys 1988; 14: 1147-1152.[Medline]
  109. Ohno S, Tomoda M, Tomisaki S et al. Improved surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patientswith carcinoma of the rectum. Dis Colon Rectum 1997; 40: 401-406.[Medline]
  110. Rau B, Wust P, Hohenberger P et al. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer. A phase II clinical study.Ann Surg 1998; 227: 380-389.[Medline]
  111. Anscher MS, Lee C, Hurwitz H et al. A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beamradiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2000; 47: 719-724.[Medline]
  112. Serin M, Erkal HS, Cakmak A. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with carcinomas of the head and neckwith N2 or N3 metastatic cervical lymph nodes. Radiother Oncol 1999; 50: 103-106.[Medline]
  113. Feyerabend T, Wiedemann GJ, Jäger B et al. Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except forinflammatory disease. Int J Radiat Oncol Biol Phys 2001; 49: 1317-1325.[Medline]
  114. Hahn GM. Introduction. In Urano M, Douple E (eds): Hyperthermia and Oncology, Volume 4. Utrecht, The Netherlands: VSP 1994: 1-7.

Sollten Sie Fragen zu Inhalten dieser Webseite haben oder als Betroffener weitere Informationen benötigen, können Sie gerne mit uns in Kontakt treten. Zur korrekten, unentgeltlichen Beantwortung Ihrer Anfragen werden alle aktuellen Unterlagen, wie Laborbefunde, OP-Berichte und CT- oder MR-Bilder benötigt.
Für die Übermittlung Ihrer Anfrage steht Ihnen das Kontaktformular zur Verfügung

Dr. med. Herwart Müller

Chefarzt der Abteilung für Allgemeinchirurgie in Wertheim
Rotkreuzklinik Wertheim
E-Mail: Herwart.Mueller@swmbrk.de
Sekretariat: Frau Anneliese Holzhäuser, Frau Birgit Rauer
E-Mail: anneliese.holzhaeuser@swmbrk.de
Telefon: 09342/303-5002
Fax:         09342/303-5001
Empfang: 09342/303-0
Rotkreuzklinik Wertheim gGmbH, Rotkreuzstr. 2
97877 Wertheim

Rotkreuzklinik Wertheim gGmbH

Abteilung für Allgemeinchirurgie
Rotkreuzstr. 2
97877 Wertheim / Bayern
+49 9342 / 303-5002


Zur Vorstellung in der Sprechstunde werden alle aktuellen Unterlagen, wie Laborbefunde, OP-Berichte und CT- oder MR-Bilder benötigt